+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

In Vivo CRO Market Size, Share & Trends Analysis Report By Model Type, By Modality, By Indication, By GLP Type, By Region, And Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 150 Pages
  • December 2024
  • Region: Global
  • Grand View Research
  • ID: 4761238

In Vivo CRO Market Growth & Trends

The global in vivo CRO market size is estimated to reach USD 7.96 billion by 2030, expanding at a CAGR of 8.13% from 2025 to 2030. The growth of the pharmaceutical market in emerging countries, along with strong demand for numerous in vivo cell therapies, rapid advancements in material sciences, and complexities of drug-device combinations, has led to the demand for services in the region. Additionally, rising in vivo preclinical and clinical research, regulatory approval, expanding services by market players, and the burden of different diseases contribute to market earnings. Also, increasing outsourcing of preclinical and clinical services across developing economies at a lower cost is one of the major factors supporting the growth of in vivo CRO market.

Likewise, the increase in offshoring drugs to emerging economies has created immense demand for the market. Budget scrutiny in developed countries, pricing pressure, and changes in reimbursement schemes are some of the major factors anticipated to increase the adoption of cost-containment measures by drug sponsors in emerging countries such as India and China. Outsourcing development services such as preclinical in vivo services to contract service providers in emerging countries is expected to boost the demand for quality assurance & regulatory affairs services, thereby contributing to the rising demand for in vivo outsourced services. Stringent processes for FDA approval and regulatory changes in the EU region are expected to make the approval process in Europe complex. They are some of the major factors contributing to the offshoring of drug companies to emerging countries.

The COVID-19 pandemic has initially negatively impacted the clinical trials industry and the in vivo CRO market was no different! The shift in the focus of the biopharmaceutical industry on developing vaccines & therapies in response to COVID-19 has resulted in the unintended consequences of potentially disrupting clinical trials for other diseases. One of the key issues faced by companies operating in the cell and gene therapy industry is the untimely delivery of therapies to patients at required clinical sites. In addition, the administration of cell-based therapeutics poses several post-pandemic challenges. Hospitals have shown hesitation in offering cell therapy services owing to concerns over transmission of SARS-CoV-2, especially to vulnerable individuals. Patients have not been able to visit cell therapy centers either owing to the lockdowns or travel bans.

Furthermore, the key participants are engaged in strategies such as mergers & acquisitions, partnerships, agreements, collaborations, and service launches, among others, to expand their global footprints and service/product portfolio. For instance, in April 2023, PsychoGenics, Inc. announced the launch of eCube, a pharmaco-electroencephalography platform, to enhance phenotypic drug discovery. Similarly, in February 2023, Biocytogen recently introduced "the Nano 100 Project" to develop over 100 fully human nanobody drugs that target specific targets. This endeavor involves combining Biocytogen's proprietary RenNano, a mouse model capable of producing fully human nanobodies, with their advanced in vitro and in vivo antibody screening platforms. By leveraging these integrated technologies, Biocytogen is poised to facilitate the extensive development of fully human nanobody drugs.

In Vivo CRO Market Report Highlights

  • The rodent-based segment held the largest revenue share of 81.95% owing to constant model demand as they are genetically similar to humans. Besides, their small size, short life cycle, ease of maintenance, and availability of genetic resources, make them the most prevalent species in in-vivo CRO research
  • The small molecule segment dominated the in vivo CRO market. The growth is attributed to the demand for small molecules in the development of drug candidates. In addition, the strong therapeutic effect of small molecules in a small dose is the key factor aiding segment growth
  • The oncology segment dominated the global in vivo CRO market and accounted for a revenue share of 29.02% in 2024, the key factors contributing to the growth include the growing burden of cancer, surging demand for new gene therapy, and preclinical studies for cancer immunotherapy. According to the American Society of Gene Cell Therapy, around 97% of CAR T-cell therapies are developed for cancer indications
  • The CNS conditions segment is anticipated to register the fastest growth, owing to the effectiveness of different model-based investigational compounds targeting brain diseases is expected to drive segment growth
  • The GLP toxicology segment dominated the market with the largest revenue share in 2024 owing to the increasing number of standardized studies conducted according to specific guidelines
  • North America held the largest revenue share of 50.0% in in-vivo CRO market in 2024. The growth in the region can be attributed to the presence of well-established market players, the increasing burden of different diseases, growing demand for CROs in the region. Other factors contributing to the growth are increased research and development activities, preclinical studies, and innovations of market players.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

Table of Contents

Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Modality
1.2.2. Model Type
1.2.3. Indication
1.2.4. GLP Type
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Parent Market Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. In Vivo CRO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Changing regulatory landscape
3.2.1.2. Increase in offshoring medical device manufacturing to emerging countries
3.2.1.3. Rising demand for advanced products
3.2.1.4. Implementation of international standards by contract manufacturers
3.2.1.5. Rising price competition and requirement to reduce cost
3.2.1.6. Increasing complexity concerning product design and engineering
3.2.2. Market Restraint Analysis
3.2.2.1. Compliance Issues While Outsourcing
3.2.2.2. Changing Scenarios in Developing Countries
3.2.2.3. Regulatory And Legal Compliance
3.2.2.4. Contractual Obligation
3.3. In Vivo CRO Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. In Vivo CRO Market: Modality Estimates & Trend Analysis
4.1. In Vivo CRO Market, By Modality: Segment Dashboard
4.2. In Vivo CRO Market, By Modality: Movement Analysis
4.3. In Vivo CRO Market Estimates & Forecasts, By Modality, 2018 - 2030
4.4. Small Molecule
4.4.1. Small Molecule Market, 2018 to 2030 (USD Million)
4.5. Large Molecule
4.5.1. Large Molecule Market, 2018 to 2030 (USD Million)
4.5.2. Cell & Gene Therapy
4.5.2.1. Cell & Gene Therapy Market, 2018 to 2030 (USD Million)
4.5.2.2. CAR T-cell therapies
4.5.2.2.1. CAR T-Cell Therapies Market, 2018 to 2030 (USD Million)
4.5.2.3. CAR-NK cell therapy
4.5.2.3.1. CAR-NK Cell Therapy Market, 2018 to 2030 (USD Million)
4.5.2.4. TCR-T cell therapy
4.5.2.4.1. TCR-T Cell Therapy Market, 2018 to 2030 (USD Million)
4.5.2.5. Other Cell & Gene Therapy
4.5.2.5.1. Other Cell & Gene Therapy Market, 2018 to 2030 (USD Million)
4.5.3. RNA Therapy
4.5.3.1. RNA Therapy Market, 2018 to 2030 (USD Million)
4.5.4. Others
4.5.4.1. Others Market, 2018 to 2030 (USD Million)
Chapter 5. In Vivo CRO Market: Model Type Estimates & Trend Analysis
5.1. In Vivo CRO Market, By Model Type: Segment Dashboard
5.2. In Vivo CRO Market, By Model Type: Movement Analysis
5.3. In Vivo CRO Market Estimates & Forecasts, By Model Type, 2018 - 2030
5.4. Rodent based
5.4.1. Rodent based Market, 2018 to 2030 (USD Million)
5.4.2. Rat Models
5.4.2.1. Rat Models Market, 2018 to 2030 (USD Million)
5.4.3. Mice Models
5.4.3.1. Mice Models Market, 2018 to 2030 (USD Million)
5.4.4. Others
5.4.4.1. Others Market, 2018 to 2030 (USD Million)
5.5. Non-Rodent based
5.5.1. Non-Rodent based Market, 2018 to 2030 (USD Million)
Chapter 6. In Vivo CRO Market: Indication Estimates & Trend Analysis
6.1. In Vivo CRO Market, By Indication: Segment Dashboard
6.2. In Vivo CRO Market, By Indication: Movement Analysis
6.3. In Vivo CRO Market Estimates & Forecasts, By Indication, 2018 - 2030
6.4. Autoimmune/inflammation conditions
6.4.1. Autoimmune/inflammation conditions Market, 2018 to 2030 (USD Million)
6.4.2. Rheumatoid Arthritis
6.4.2.1. Rheumatoid Arthritis Market, 2018 to 2030 (USD Million)
6.4.3. Multiple Sclerosis
6.4.3.1. Multiple Sclerosis Market, 2018 to 2030 (USD Million)
6.4.4. Osteoarthritis
6.4.4.1. Osteoarthritis Market, 2018 to 2030 (USD Million)
6.4.5. Irritable Bowel Syndrome
6.4.5.1. Irritable Bowel Syndrome Market, 2018 to 2030 (USD Million)
6.4.6. Others
6.4.6.1. Others Market, 2018 to 2030 (USD Million)
6.5. Pain management
6.5.1. Pain management Market, 2018 to 2030 (USD Million)
6.5.2. Chronic pain
6.5.2.1. Chronic pain Market, 2018 to 2030 (USD Million)
6.5.3. Acute pain
6.5.3.1. Acute pain Market, 2018 to 2030 (USD Million)
6.6. Oncology
6.6.1. Oncology Market, 2018 to 2030 (USD Million)
6.6.2. Blood cancer
6.6.2.1. Blood Cancer Market, 2018 to 2030 (USD Million)
6.6.3. Solid tumor
6.6.3.1. Solid Tumor Market, 2018 to 2030 (USD Million)
6.6.3.2. Syngeneic model
6.6.3.2.1. Syngeneic Model Market, 2018 to 2030 (USD Million)
6.6.3.3. Patient derived xenograft
6.6.3.3.1. Patient Derived Xenograft Market, 2018 to 2030 (USD Million)
6.6.3.4. Xenograft
6.6.3.4.1. Xenograft Market, 2018 to 2030 (USD Million)
6.6.4. Others
6.6.4.1. Others Market, 2018 to 2030 (USD Million)
6.7. CNS Conditions
6.7.1. CNS Conditions Market, 2018 to 2030 (USD Million)
6.7.2. Epilepsy
6.7.2.1. Epilepsy Market, 2018 to 2030 (USD Million)
6.7.3. Parkinson's disease
6.7.3.1. Parkinson's Disease Market, 2018 to 2030 (USD Million)
6.7.4. Huntington's disease
6.7.4.1. Huntington's Disease Market, 2018 to 2030 (USD Million)
6.7.5. Stroke
6.7.5.1. Stroke Market, 2018 to 2030 (USD Million)
6.7.6. Muscular Dystrophy
6.7.6.1. Muscular Dystrophy Market, 2018 to 2030 (USD Million)
6.7.7. Alzheimer’s Disease
6.7.7.1. Alzheimer’s Disease Market, 2018 to 2030 (USD Million)
6.7.8. Traumatic brain injury
6.7.8.1. Traumatic Brain Injury Market, 2018 to 2030 (USD Million)
6.7.9. Amyotrophic lateral sclerosis (ALS)
6.7.9.1. Amyotrophic Lateral Sclerosis (ALS) Market, 2018 to 2030 (USD Million)
6.7.10. Spinal Muscular Atrophy
6.7.10.1. Spinal Muscular Atrophy Market, 2018 to 2030 (USD Million)
6.7.11. Muscle regeneration
6.7.11.1. Muscle Regeneration Market, 2018 to 2030 (USD Million)
6.7.12. Other Neurodevelopment Disorders
6.7.12.1. Other Neurodevelopment Disorders Market, 2018 to 2030 (USD Million)
6.8. Diabetes
6.8.1. Diabetes Market, 2018 to 2030 (USD Million)
6.9. Obesity
6.9.1. Obesity Market, 2018 to 2030 (USD Million)
6.10. Others
6.10.1. Others Market, 2018 to 2030 (USD Million)
Chapter 7. In Vivo CRO Market: GLP Type Estimates & Trend Analysis
7.1. In Vivo CRO Market, By GLP Type: Segment Dashboard
7.2. In Vivo CRO Market, By GLP Type: Movement Analysis
7.3. In Vivo CRO Market Estimates & Forecasts, By GLP Type, 2018 - 2030
7.4. Non GLP
7.4.1. Non GLP Market, 2018 to 2030 (USD Million)
7.5. GLP Toxicology
7.5.1. GLP Toxicology based Market, 2018 to 2030 (USD Million)
Chapter 8. In Vivo CRO Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. North America
8.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.2. U.S
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Regulatory Framework
8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.3. Canada
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. Regulatory Framework
8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4.4. Mexico
8.4.4.1. Key Country Dynamics
8.4.4.2. Competitive Scenario
8.4.4.3. Regulatory Framework
8.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. Europe
8.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.2. UK
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Framework
8.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.3. Germany
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Framework
8.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.4. France
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Regulatory Framework
8.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.5. Italy
8.5.5.1. Key Country Dynamics
8.5.5.2. Competitive Scenario
8.5.5.3. Regulatory Framework
8.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.6. Spain
8.5.6.1. Key Country Dynamics
8.5.6.2. Competitive Scenario
8.5.6.3. Regulatory Framework
8.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.7. Denmark
8.5.7.1. Key Country Dynamics
8.5.7.2. Competitive Scenario
8.5.7.3. Regulatory Framework
8.5.7.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.8. Sweden
8.5.8.1. Key Country Dynamics
8.5.8.2. Competitive Scenario
8.5.8.3. Regulatory Framework
8.5.8.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5.9. Norway
8.5.9.1. Key Country Dynamics
8.5.9.2. Competitive Scenario
8.5.9.3. Regulatory Framework
8.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.2. Japan
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Framework
8.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.3. China
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.4. India
8.6.4.1. Key Country Dynamics
8.6.4.2. Competitive Scenario
8.6.4.3. Regulatory Framework
8.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.5. South Korea
8.6.5.1. Key Country Dynamics
8.6.5.2. Competitive Scenario
8.6.5.3. Regulatory Framework
8.6.5.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.6. Australia
8.6.6.1. Key Country Dynamics
8.6.6.2. Competitive Scenario
8.6.6.3. Regulatory Framework
8.6.6.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6.7. Thailand
8.6.7.1. Key Country Dynamics
8.6.7.2. Competitive Scenario
8.6.7.3. Regulatory Framework
8.6.7.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.7. Latin America
8.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. Competitive Scenario
8.7.2.3. Regulatory Framework
8.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. Competitive Scenario
8.7.3.3. Regulatory Framework
8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.8. MEA
8.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. Competitive Scenario
8.8.2.3. Regulatory Framework
8.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. Competitive Scenario
8.8.3.3. Regulatory Framework
8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. Competitive Scenario
8.8.4.3. Regulatory Framework
8.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. Competitive Scenario
8.8.5.3. Regulatory Framework
8.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Market Participant Categorization
9.2. Company Market Share Analysis, 2023/24
9.3. Company Profiles
9.3.1. IQVIA Inc
9.3.1.1. Company Overview
9.3.1.2. Financial Performance
9.3.1.3. Service Benchmarking
9.3.1.4. Strategic Initiatives
9.3.2. Crown Bioscience
9.3.2.1. Company Overview
9.3.2.2. Financial Performance
9.3.2.3. Service Benchmarking
9.3.2.4. Strategic Initiatives
9.3.3. Taconic Biosciences, Inc.
9.3.3.1. Company Overview
9.3.3.2. Financial Performance
9.3.3.3. Service Benchmarking
9.3.3.4. Strategic Initiatives
9.3.4. PsychoGenics Inc.
9.3.4.1. Company Overview
9.3.4.2. Financial Performance
9.3.4.3. Service Benchmarking
9.3.4.4. Strategic Initiatives
9.3.5. Evotec
9.3.5.1. Company Overview
9.3.5.2. Financial Performance
9.3.5.3. Service Benchmarking
9.3.5.4. Strategic Initiatives
9.3.6. Janvier Labs
9.3.6.1. Company Overview
9.3.6.2. Financial Performance
9.3.6.3. Service Benchmarking
9.3.6.4. Strategic Initiatives
9.3.7. Biocytogen
9.3.7.1. Company Overview
9.3.7.2. Financial Performance
9.3.7.3. Service Benchmarking
9.3.7.4. Strategic Initiatives
9.3.8. GemPharmatech
9.3.8.1. Company Overview
9.3.8.2. Financial Performance
9.3.8.3. Service Benchmarking
9.3.8.4. Strategic Initiatives
9.3.9. Charles River Laboratories
9.3.9.1. Company Overview
9.3.9.2. Financial Performance
9.3.9.3. Service Benchmarking
9.3.9.4. Strategic Initiatives
9.3.10. Icon Plc
9.3.10.1. Company Overview
9.3.10.2. Financial Performance
9.3.10.3. Service Benchmarking
9.3.10.4. Strategic Initiatives
9.3.11. Labcorp Drug Development
9.3.11.1. Company Overview
9.3.11.2. Financial Performance
9.3.11.3. Service Benchmarking
9.3.11.4. Strategic Initiatives
9.3.12. Parexel International Corporation
9.3.12.1. Company Overview
9.3.12.2. Financial Performance
9.3.12.3. Service Benchmarking
9.3.12.4. Strategic Initiatives
9.3.13. SMO Clinical Research (I) Pvt Ltd
9.3.13.1. Company Overview
9.3.13.2. Financial Performance
9.3.13.3. Service Benchmarking
9.3.13.4. Strategic Initiatives
Chapter 10 Key Recommendations
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global In Vivo CRO Market, By Region, 2018 - 2030 (USD Million)
Table 4 Global In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 5 Global In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 6 Global In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 7 Global In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 8 North America In Vivo CRO Market, By Country, 2018 - 2030 (USD Million)
Table 9 North America In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 10 North America In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 11 North America In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 12 North America In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 13 U.S. In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 14 U.S. In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 15 U.S. In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 16 U.S. In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 17 Canada In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 18 Canada In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 19 Canada In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 20 Canada In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 21 Mexico In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 22 Mexico In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 23 Mexico In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 24 Mexico In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 25 Europe In Vivo CRO Market, By Country, 2018 - 2030 (USD Million)
Table 26 Europe In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 27 Europe In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 28 Europe In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 29 Europe In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 30 UK In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 31 UK In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 32 UK In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 33 UK In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 34 Germany In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 35 Germany In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 36 Germany In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 37 Germany In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 38 France In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 39 France In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 40 France In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 41 France In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 42 Italy In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 43 Italy In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 44 Italy In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 45 Italy In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 46 Spain In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 47 Spain In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 48 Spain In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 49 Spain In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 50 Denmark In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 51 Denmark In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 52 Denmark In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 53 Denmark In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 54 Sweden In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 55 Sweden In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 56 Sweden In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 57 Sweden In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 58 Norway In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 59 Norway In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 60 Norway In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 61 Norway In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 62 Asia Pacific In Vivo CRO Market, By Country, 2018 - 2030 (USD Million)
Table 63 Asia Pacific In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 64 Asia Pacific In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 65 Asia Pacific In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 66 Asia Pacific In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 67 Japan In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 68 Japan In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 69 Japan In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 70 Japan In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 71 China In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 72 China In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 73 China In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 74 China In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 75 India In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 76 India In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 77 India In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 78 India In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 79 South Korea In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 80 South Korea In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 81 South Korea In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 82 South Korea In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 83 Australia In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 84 Australia In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 85 Australia In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 86 Australia In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 87 Thailand In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 88 Thailand In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 89 Thailand In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 90 Thailand In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 91 Latin America In Vivo CRO Market, By Country, 2018 - 2030 (USD Million)
Table 92 Latin America In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 93 Latin America In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 94 Latin America In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 95 Latin America In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 96 Brazil In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 97 Brazil In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 98 Brazil In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 99 Brazil In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 100 Argentina In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 101 Argentina In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 102 Argentina In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 103 Argentina In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 104 Middle East and Africa In Vivo CRO Market, By Country, 2018 - 2030 (USD Million)
Table 105 Middle East and Africa In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 106 Middle East and Africa In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 107 Middle East and Africa In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 108 Middle East and Africa In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 109 South Africa In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 110 South Africa In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 111 South Africa In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 112 South Africa In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 113 Saudi Arabia In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 114 Saudi Arabia In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 115 Saudi Arabia In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 116 Saudi Arabia In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 117 UAE In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 118 UAE In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 119 UAE In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 120 UAE In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
Table 121 Kuwait In Vivo CRO Market, By Model Type, 2018 - 2030 (USD Million)
Table 122 Kuwait In Vivo CRO Market, By Modality, 2018 - 2030 (USD Million)
Table 123 Kuwait In Vivo CRO Market, By Indication, 2018 - 2030 (USD Million)
Table 124 Kuwait In Vivo CRO Market, By GLP Type, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 In Vivo CRO Market Segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Data Analysis Models
Fig. 6 Market Formulation And Validation
Fig. 7 Data Validating & Publishing
Fig. 8 Parent Market Analysis
Fig. 9 Service/Commodity Flow Analysis
Fig. 10 Value-Chain-Based Sizing & Forecasting
Fig. 11 QFD Model Sizing & Forecasting
Fig. 12 Market formulation & validation
Fig. 13 Market Snapshot
Fig. 14 Segment Snapshot
Fig. 15 Competitive landscape snapshot
Fig. 16 Parent market analysis, 2024 (USD Million)
Fig. 17 Ancillary market outlook, 2024 (USD Million)
Fig. 18 In vivo CRO market dynamics
Fig. 19 FDA expedited approval pathway
Fig. 20 Porter’s Five Forces Analysis
Fig. 21 SWOT analysis by factor (political, legal, economic, social, environmental, and technological)
Fig. 22 Companies With Affected Trials, By Size
Fig. 23 Affected Trials, By Study Phase
Fig. 24 Clinical trial scenario (As of January 2023/24)
Fig. 25 In vivo CRO market model type outlook: Segment dashboard
Fig. 26 In vivo CRO Market, by model type segment: Market Share, 2024 & 2030
Fig. 27 Rodent-based market, 2018 - 2030 (USD Million)
Fig. 28 Rat model market, 2018 - 2030 (USD Million)
Fig. 29 Mice model market, 2018 - 2030 (USD Million)
Fig. 30 Others market, 2018 - 2030 (USD Million)
Fig. 31 Non rodent-based market, 2018 - 2030 (USD Million)
Fig. 32 In vivo CRO market, by indication segment: Market Share, 2024 & 2030
Fig. 33 Autoimmune/inflammatory conditions market, 2018 - 2030 (USD Million)
Fig. 34 Rheumatoid arthritis market, 2018 - 2030 (USD Million)
Fig. 35 Multiple sclerosis market, 2018 - 2030 (USD Million)
Fig. 36 Osteoarthritis market, 2018 - 2030 (USD Million)
Fig. 37 Irritable bowel syndrome market, 2018 - 2030 (USD Million)
Fig. 38 Others market, 2018 - 2030 (USD Million)
Fig. 39 Pain management market, 2018 - 2030 (USD Million)
Fig. 40 Chronic pain market, 2018 - 2030 (USD Million)
Fig. 41 Acute pain market, 2018 - 2030 (USD Million)
Fig. 42 Oncology market, 2018 - 2030 (USD Million)
Fig. 43 Blood cancer market, 2018 - 2030 (USD Million)
Fig. 44 Solid tumor market, 2018 - 2030 (USD Million)
Fig. 45 Syngeneic model market, 2018 - 2030 (USD Million)
Fig. 46 Patient derived xenograft market, 2018 - 2030 (USD Million)
Fig. 47 Xenograft market, 2018 - 2030 (USD Million)
Fig. 48 Others oncology types market, 2018 - 2030 (USD Million)
Fig. 49 CNS conditions market, 2018 - 2030 (USD Million)
Fig. 50 Epilepsy market, 2018 - 2030 (USD Million)
Fig. 51 The Parkinson’s development pipeline by phase
Fig. 52 Parkinson’s disease market, 2018 - 2030 (USD Million)
Fig. 53 Huntington’s disease market, 2018 - 2030 (USD Million)
Fig. 54 Stroke market, 2018 - 2030 (USD Million)
Fig. 55 Traumatic brain injury market, 2018 - 2030 (USD Million)
Fig. 56 Amyotrophic Lateral Sclerosis (ALS) market, 2018 - 2030 (USD Million)
Fig. 57 Muscle regeneration market, 2018 - 2030 (USD Million)
Fig. 58 Alzheimer’s development pipeline, by phase
Fig. 59 Alzheimer’s development pipeline, by disease severity
Fig. 60 Alzheimer’s disease market, 2018 - 2030 (USD Million)
Fig. 61 Spinal muscular atrophy market, 2018 - 2030 (USD Million)
Fig. 62 Muscular dystrophy market, 2018 - 2030 (USD Million)
Fig. 63 Neurodevelopment disorders market, 2018 - 2030 (USD Million)
Fig. 64 Diabetes market, 2018 - 2030 (USD Million)
Fig. 65 Obesity market, 2018 - 2030 (USD Million)
Fig. 66 Others market, 2018 - 2030 (USD Million)
Fig. 67 In Vivo CRO Market Modality Type Outlook:Segment dashboard
Fig. 68 In Vivo CRO Market, By Modality Type Segment: Market Share, 2024 & 2030
Fig. 69 Large molecule market, 2018 - 2030 (USD Million)
Fig. 70 Cell and gene therapies market, 2018 - 2030 (USD Million)
Fig. 71 CAR-T cell therapies market, 2018 - 2030 (USD Million)
Fig. 72 CAR-NK cell therapies market, 2018 - 2030 (USD Million)
Fig. 73 TCR-T cell therapy market, 2018 - 2030 (USD Million)
Fig. 74 Other market, 2018 - 2030 (USD Million)
Fig. 75 RNA therapy market, 2018 - 2030 (USD Million)
Fig. 76 Others market, 2018 - 2030 (USD Million)
Fig. 77 Small molecules market, 2018 - 2030 (USD Million)
Fig. 78 In Vivo CRO Market GLP Type Outlook: Segment dashboard
Fig. 79 In Vivo CRO Market, By GLP Type Segment: Market Share, 2024 & 2030
Fig. 80 GLP Toxicology Market, 2018 - 2030 (USD Million)
Fig. 81 Non-GLP Market, 2018 - 2030 (USD Million)
Fig. 82 In vivo CRO market revenue, by region, 2024 & 2030 (USD Million)
Fig. 83 Regional market share analysis, 2024 & 2030
Fig. 84 Regional marketplace: key takeaways
Fig. 85 Regional marketplace: key takeaways
Fig. 86 North America in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 87 Key country dynamics
Fig. 88 U.S. in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 89 Key country dynamics
Fig. 90 Canada in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 91 Key country dynamics
Fig. 92 Mexico in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 93 Europe in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 94 Key country dynamics
Fig. 95 Germany in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 96 Key country dynamics
Fig. 97 UK in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 98 Key country dynamics
Fig. 99 France in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 100 Key country dynamics
Fig. 101 Spain in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 102 Key country dynamics
Fig. 103 Italy in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 104 Key country dynamics
Fig. 105 Denmark in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 106 Key country dynamics
Fig. 107 Sweden in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 108 Key country dynamics
Fig. 109 Italy in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 110 Asia Pacific in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 111 Key Country Dynamics
Fig. 112 Japan in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 113 Key Country Dynamics
Fig. 114 China In vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 115 Key Country Dynamics
Fig. 116 India in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 117 Key Country Dynamics
Fig. 118 Australia in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 119 Key Country Dynamics
Fig. 120 South Korea in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 121 Key country dynamic
Fig. 122 Thailand in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 123 Latin America in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 124 Key country dynamics
Fig. 125 Brazil in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 126 Key country dynamics
Fig. 127 Argentina in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 128 MEA in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 129 Key country dynamics
Fig. 130 South Africa in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 131 Key country dynamics
Fig. 132 Saudi Arabia in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 133 Key country dynamics
Fig. 134 UAE in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 135 Key country dynamics
Fig. 136 Kuwait in vivo CRO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 137 Key company categorization
Fig. 138 Company market position analysis
Fig. 139 In Vivo CRO Market Share Analysis, 2023
Fig. 140 Strategic framework

Companies Mentioned

  • IQVIA Inc
  • Crown Bioscience
  • Taconic Biosciences, Inc.
  • PsychoGenics Inc.
  • Evotec
  • Janvier Labs
  • Biocytogen
  • GemPharmatech
  • Charles River Laboratories
  • Icon Plc
  • Labcorp Drug Development
  • Parexel International Corporation
  • SMO Clinical Research (I) Pvt Ltd

Methodology

Loading
LOADING...

Table Information